MS-Selfie cover art

All Episodes

MS-Selfie — 160 episodes

#
Title
1

Should my MS be hit hard and early?

2

Q&A: managing advanced MS

3

Pressure sores

4

Should I be worried about measles?

5

Male and female-specific MS care pathways

6

Gender inequality in MS care

7

Q&A 139 - tolebrutinib and the FDA

8

Necessary, but insufficient

9

New MS subtypes or not?

10

Sylvia

11

Christmas 2025

12

Treating mono: will it become a reality?

13

Dissociative states and MS

14

Are we neglecting primary progressive MS?

15

O Canada

16

Challenging the dogma around the focal MS lesion

17

Do you know how to measure your blood pressure?

18

EBV vaccine killjoys

19

Preventing multiple sclerosis by vaccination

20

Dithering neurologists

21

Merry Christmas

22

Relapses versus Progression

23

Are you a hoarder?

24

Q&A 55: Should I have a third course of cladribine?

25

#1 ECTRIMS 2024 - battle of the BTKi's

26

Insomnia and multiple sclerosis

27

Farewell - no fanfare

28

What to do about MS follow-up consultations that are too short?

29

Are MS treatment algorithms good or bad?

30

Artificial sweeteners, taste and multiple sclerosis

31

Prof G is retiring

32

Exercise matters

33

Self-management and a rose-tinted-odometer

34

Placebo-controlled phase 2 trials

35

Music therapy: under appreciated but not forgotten

36

HPV infection and DMTs

37

Molluscum contagiosum on fingolimod

38

Rectal bleeding: how to approach symptoms that may or may not be related to having MS

39

Case study - feet swelling

40

Will Frexalimab replace the anti-CD20s?

41

Dehydration and bladder function

42

Baclofen zombie

43

Evobrutinib is no better than teriflunomide

44

AHSCT vs. CAR T-cells to treat MS

45

MS-GPT - your AI enabled MS guide

46

Sleep glorious sleep

47

Worsening cognition: ageing vs. smouldering MS

48

Principles underpinning the treatment of MS

49

The Murray Bornstein Memorial Lecture

50

Is there a need for MS self-management flowcharts or algorithms?

51

Multiple sclerosis and seizures

52

To cure or not to cure MS, that is the question

53

Do you suffer from restless legs syndrome?

54

Gum disease and MS

55

Onychogryphosis

56

Does burnt out MS exist?

57

Multiple sclerosis recognised as a global problem

58

What has a scrubbing brush got to do with multiple sclerosis?

59

Case study: facial twitching as a first manifestation of MS

60

NHS strikes: implications for the future management of MS

61

Yellow fever vaccination

62

MS-Related Intertrigo

63

Happy 75th Birthday NHS

64

How is your gut health?

65

MS self-management (MS-Selfie) microsite

66

CNS resilience in progression of MS

67

The annual MS follow-up consultation

68

Managing expectations

69

Nutraceuticals: what is the state of play in MS?

70

Is it ethical to use teriflunomide as an active comparator in phase 3 trials?

71

#MSConnections: have you connected with Barbellion?

72

Is shared-decision making dead?

73

How important is the diagnosis and management of infectious mono?

74

Beyond the B-cell - an alternative treatment paradigm for MS

75

AAN 2023: what is the greatest unmet need in MS?

76

Should I switch from ocrelizumab to ofatumumab?

77

Prof G chastised for discussing the real MS

78

Multidisciplinary MS Team Meetings or MDTs: can we leverage them to 'Raise-the-Bar'?

79

Why is Prof G so disheartened?

80

Info cards for making decision about DMTs

81

Diagnosing MS: what to expect?

82

Case study: gaslit for mentioning smouldering MS

83

Sudden death in MS is very very rare

84

Smouldering MS - a new trial

85

Making the case for AHSCT being first-line

86

The management of MS in the future

87

EBV immunotherapy for MS: glofitamab induction

88

STAR-MS: AHSCT as a first-line therapy for MS

89

Attack MS

90

Hip pain in people with MS

91

St Elsewhere Hospital - delayed MS diagnosis

92

Inappropriate laughing and crying

93

Flasbacks - PTSD

94

Is your MS salvageable?

95

ECTRIMS 2022 - highlights

96

ECTRIMS 2022 - initial thoughts

97

EBV & MS - repeating oneself is often a good thing

98

Multiple sclerosis with a near-normal MRI

99

Brain Health: how important is it?

100

How strong is your pelvic floor?

101

The MS-Selfie logo

102

How to interpret a urine dipstick result

103

Is primary progressive MS a different disease?

104

The Perfect Storm

105

More evidence that EBV causes MS

106

Tinnitus: don't always blame MS

107

Medical gaslighting

108

Reflections: setting priorities for MS

109

Falls: is there anything that can be done to help?

110

COVID-19 update - BA5

111

Heat - what to do?

112

Cog-fog and fatigue

113

Case study: oscillopsia or jumpy vision

114

EBV antivirals to treat MS

115

Crossword puzzle #2

116

Why is natalizumab not licensed to treat progressive MS?

117

MS-Selfie Crossword

118

Grit: do you have what it takes?

119

Time matters: should British people with MS accept sup-optimal care?

120

Case study: how much brain have you lost?

121

Can you have a relapse affecting the same site?

122

What is my neurofilament level doing?

123

Waist-to-height ratio, metabolic health and MS

124

MS biohackers beware

125

Case study: Copaxone, menstruation and the menopause

126

Why did subcutaneous natalizumab (Tysabri) get rejected by the FDA?

127

Neurological stress tests

128

The retrospectoscope

129

Spring COVID-19 Update

130

War: a forgotten social determinant of health

131

Exercise, exercise, exercise ... how important is it?

132

Is there still a role for glatiramer acetate in the management of MS?

133

Case study: stress as trigger of relapses

134

Making the case for antiviral therapies in MS

135

Case study: does treating MS early improve survival?

136

Serum neurofilament levels - another one bites the dust?

137

COVID-19 update: the BA.2 variant and miscellanea

138

Is there still a role for interferon-beta in the management of MS?

139

Research: big data and smouldering MS

140

Are you and your family taking vitamin D supplements?

141

The rag-doll effect

142

Do you have smouldering MS?

143

Case study: why cladribine is the better option in this case than ocrelizumab

144

Case study: why is having another autoimmune disease a contraindication to alemtuzumab?

145

More evidence that EBV is the cause of MS

146

Case study: is delayed or adaptive ocrelizumab dosing safer?

147

Case study: am I having a relapse?

148

Case study: are we ready for adaptive ocrelizumab dosing?

149

Is Omicron a new variant or a new strain of SARS-CoV-2?

150

MS & headache: another elephant in the room

151

Diet, obesity and MS outcomes - it's your choice

152

D is for Denial

153

Teach Neurology: lymphopaenia

154

Case study: MRI-negative relapses

155

An online course to self-manage MS or not?

156

Black Friday

157

Case study: pulse oximetry

158

Are you eligible for an MS disease-modifying therapy?

159

Case study: Ronapreve prophylaxis vs. it as a therapeutic

160

TeachNeuro: fingolimod rebound